secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evelo Biosciences, Inc. (—)
CIK:        0001694665
Form:       8-K
Filed at:   2023-12-04T23:59:59+00:00
Accession:  0001193125-23-287901
Event type: regulatory
Sentiment:  negative
Materiality: 0.95
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Evelo Biosciences receives Nasdaq delisting notice; will not appeal; trading suspension Dec 12
--------------------------------------------------------------------------------

- Nasdaq determined Evelo is a 'public shell' after board resignations, CEO/CFO separation, and dissolution plan.
- Company fails $50M market value, $15M public float, and $1 bid price requirements for continued listing.
- Trading suspended at open on Dec 12, 2023; Form 25-NSE to follow; company will not appeal.
- Stockholders may realize no value as company proceeds with dissolution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1694665/000119312523287901/0001193125-23-287901-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1694665/000119312523287901/d622413d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-287901

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer